Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma ...
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...
Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...
Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A third of patients with relapsed/refractory multiple myeloma ...
Arcellx (ACLX) and Legend Biotech (LEGN) traded higher on Tuesday after the U.S. FDA issued draft guidance on the use of ...
Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...
Please provide your email address to receive an email when new articles are posted on . A triplet regimen extended OS compared with the current standard of care for patients with relapsed or ...
Vietnam Investment Review on MSN
Innovent Gains FDA Fast Track for Cancer Drug
SAN FRANCISCO and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results